Source:http://linkedlifedata.com/resource/pubmed/id/19767783
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-5-12
|
pubmed:abstractText |
Acute graft vs host disease (aGVHD) is a significant obstacle to successful allogeneic hematopoietic cell transplantation, as only 30-40% of those with aGVHD show complete response to front-line glucocorticoids. The role of mycophenolate mofetil (MMF) as salvage therapy in steroid-refractory aGVHD remains incompletely defined. Here, we examine outcomes of 27 patients with refractory aGVHD treated with MMF as second-line therapy. Seven (26%) patients achieved complete remission (CR) of steroid-refractory aGVHD with only the addition of MMF as salvage therapy. CR of aGVHD differed by overall grade at salvage (grade I, 1/3; grade II, 5/12; grade III 0/5; grade IV, 1/7) with odds ratio for CR in grade I/II vs III/IV of 7.3 (95% CI: 0.7-72.6, P=0.09). Overall survival (OS) at 3 years was 40%. Overall aGVHD grade at salvage (hazard ratio (HR) grade I/II vs III/IV 0.18 (95% CI: 0.06-0.57), P=0.003) and achievement of CR (HR 0.12 (95% CI: 0.04-0.39), P=0.0004) were significant predictors of OS. MMF was overall well tolerated, with only two patients requiring discontinuation for myelosuppression. MMF shows activity in the salvage of steroid-refractory, grades I-II aGVHD.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1476-5365
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
919-24
|
pubmed:meshHeading |
pubmed-meshheading:19767783-Acute Disease,
pubmed-meshheading:19767783-Adult,
pubmed-meshheading:19767783-Drug Resistance,
pubmed-meshheading:19767783-Glucocorticoids,
pubmed-meshheading:19767783-Graft vs Host Disease,
pubmed-meshheading:19767783-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19767783-Humans,
pubmed-meshheading:19767783-Maximum Tolerated Dose,
pubmed-meshheading:19767783-Middle Aged,
pubmed-meshheading:19767783-Mycophenolic Acid,
pubmed-meshheading:19767783-Remission Induction,
pubmed-meshheading:19767783-Salvage Therapy,
pubmed-meshheading:19767783-Survival Analysis,
pubmed-meshheading:19767783-Tissue Donors,
pubmed-meshheading:19767783-Transplantation, Homologous,
pubmed-meshheading:19767783-Treatment Outcome
|
pubmed:year |
2010
|
pubmed:articleTitle |
Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease.
|
pubmed:affiliation |
Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612-9416, USA. joseph.pidala@moffitt.org
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|